This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database.
All Wales Medicines Strategy Group (AWMSG). Brimonidine (Mirvaso®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2168. 2015
Brimonidine (Mirvaso®) is recommended for restricted use within NHS Wales for the symptomatic treatment of facial erythema of rosacea in adult patients. Brimonidine (Mirvaso®) should be restricted for use in patients with moderate to severe persistent facial erythema associated with rosacea. Brimonidine (Mirvaso®) is not recommended for use within NHS Wales outside of this subpopulation.
Subject indexing assigned by CRD
Adults; Erythema; Quinoxalines; Rosacea
Country of organisation
An English language summary is available.
Address for correspondence
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Date abstract record published